Home > > > > > Report Detail

Contraceptives - Pipeline Insight, 2020

Publisher Name :
Date: 16-Jan-2020
No. of pages: 90
Delivery of the Report will take 2-3 working days once order is placed.

Contraceptives Overview

"Contraceptives Pipeline Insight, 2020" Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Contraceptives Market. A Detailed Picture Of The Contraceptives Pipeline Landscape Is Provided, Which Includes The Disease Overview And Contraceptives Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Contraceptives Commercial Assessment And Clinical Assessment Of The Contraceptives Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Contraceptives Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

Contraceptives Of Pipeline Development Activities

The Report Provides Insights Into:

- All Of The Companies That Are Developing Therapies For The Treatment Of Contraceptives With Aggregate Therapies Developed By Each Company For The Same.

- Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Contraceptives Treatment.

- Contraceptives Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.

- Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.

- Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Contraceptives Market.

- The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

Contraceptives Analytical Perspective By DelveInsight

- In-Depth Contraceptives Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

- Contraceptives Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

Scope Of The Report

- The Contraceptives Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Contraceptives Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.

- It Comprises Of Detailed Profiles Of Contraceptives Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details

- Detailed Contraceptives Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.

- Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Contraceptives.

Report Highlights

- A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Contraceptives.

- In The Coming Years, The Contraceptives Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.

- The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Contraceptives R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.

- A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Contraceptives Treatment Market. Several Potential Therapies For Contraceptives Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Contraceptives Market Size In The Coming Years.

- Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Contraceptives ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

Key Questions

- What Are The Current Options For Contraceptives Treatment?

- How Many Companies Are Developing Therapies For The Treatment Of Contraceptives?

- What Are The Principal Therapies Developed By These Companies In The Industry?

- How Many Therapies Are Developed By Each Company For The Treatment Of Contraceptives?

- How Many Contraceptives Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Contraceptives?

- Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?

- What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Contraceptives Market?

- Which Are The Dormant And Discontinued Products And The Reasons For The Same?

- What Is The Unmet Need For Current Therapies For The Treatment Of Contraceptives?

- What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Contraceptives Therapies?

- What Are The Clinical Studies Going On For Contraceptives And Their Status?

- What Are The Results Of The Clinical Studies And Their Safety And Efficacy?

- What Are The Key Designations That Have Been Granted For The Emerging Therapies For Contraceptives?

- How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Contraceptives?

Contraceptives - Pipeline Insight, 2020

Table of Contents

1. Report Introduction
2. Contraceptives
2.1. Overview
2.2. History
2.3. Contraceptives Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Contraceptives Diagnosis
2.6.1. Diagnostic Guidelines
3. Contraceptives Current Treatment Patterns
3.1. Contraceptives Treatment Guidelines
4. Contraceptives - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Contraceptives companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Contraceptives Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Contraceptives Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Contraceptives Late Stage Products (Phase-III)
7. Contraceptives Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Contraceptives Discontinued Products
13. Contraceptives Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Contraceptives Key Companies
15. Contraceptives Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Contraceptives Unmet Needs
18. Contraceptives Future Perspectives
19. Contraceptives Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

List of Tables

Table 1: Contraceptives Diagnostic Guidelines
Table 2: Contraceptives Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Contraceptives Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Contraceptives Late Stage Products (Phase-III)
Table 18: Contraceptives Mid Stage Products (Phase-II)
Table 19: Contraceptives Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products

List of Figures

Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Contraceptives companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Contraceptives Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
  • Global Drugs for Vulvovaginal Candidiasis Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 798.8 million in 2023. With growing demand in downstream market, the Drugs for Vulvovaginal Candidiasis is forecast to a readjusted size of US$ 890 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Drugs for Vulvovaginal Candidiasis market. Drugs for Vulvovaginal Candidiasis are expected t......
  • Global Bacterial Vaginosis Drug Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132
    According to our LPI (LP Information) latest study, the global Bacterial Vaginosis Drug market size was valued at US$ 896.6 million in 2023. With growing demand in downstream market, the Bacterial Vaginosis Drug is forecast to a readjusted size of US$ 1111.1 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Bacterial Vaginosis Drug market. Bacterial Vaginosis Drug are expected to show stable growth in the future ma......
  • Global Contraceptives Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 141
    According to our LPI (LP Information) latest study, the global Contraceptives market size was valued at US$ 1870.3 million in 2023. With growing demand in downstream market, the Contraceptives is forecast to a readjusted size of US$ 2237.4 million by 2030 with a CAGR of 2.6% during review period. The research report highlights the growth potential of the global Contraceptives market. Contraceptives are expected to show stable growth in the future market. However, product differentiation,......
  • Global Drugs for Vulvovaginal Candidiasis Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 108
    According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at USD 840.2 million in 2023 and is forecast to a readjusted size of USD 928.4 million by 2030 with a CAGR of 1.4% during review period. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cu......
  • Global Menopausal Hot Flashes Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Menopausal Hot Flashes market: According to our latest research, the global Menopausal Hot Flashes market looks promising in the next 5 years. As of 2022, the global Menopausal Hot Flashes market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Hot flashes during menopause are symptoms of menopause. They refer to the warmth that occurs during the transition period of ......
  • Global Bacterial Vaginosis Drug Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 139
    Report Overview: This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs. The Global Bacterial Vaginosis Drug Market Size was estimated at USD 916.50 million in 2022 and is projected to reach USD 1127.18 million by 202......
  • Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122
    Report Overview: The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for a......
  • Global Bacterial Vaginosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Bacterial Vaginosis Drug market: According to our latest research, the global Bacterial Vaginosis Drug market looks promising in the next 5 years. As of 2022, the global Bacterial Vaginosis Drug market was estimated at USD 972.77 million, and it's anticipated to reach USD 1215.68 million in 2028, with a CAGR of 3.79% during the forecast years. Bacterial vaginosis (BV), also known as bacterial vaginosis, non-specific vaginitis is a disease that occurs......
  • Global Tocolysis Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 123
    Market Overview of Global Tocolysis Drugs market: According to our latest research, the global Tocolysis Drugs market looks promising in the next 5 years. As of 2022, the global Tocolysis Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Tocolytics are medications used to suppress premature labor. Tocolytic therapy is provided when delivery would result in premature birth, postponi......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs